TriSalus Life Sciences (TLSI) Free Cash Flow (2021 - 2026)

TriSalus Life Sciences' Free Cash Flow history runs 6 years deep, the most recent figure standing at -$6.6 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 44.37% year-over-year to -$6.6 million in Q1 2026; TTM through Mar 2026 was -$20.1 million, a 41.69% increase from a year earlier, with the FY2025 full-year figure at -$18.1 million, up 55.73% from the prior year.
• Free Cash Flow eased to -$6.6 million in Q1 2026 per TLSI's latest filing, from -$1.7 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$425954.0 in Q1 2022 and bottomed at -$22.9 million in Q3 2022.
• The 5-year median for Free Cash Flow is -$7.9 million (2022), against an average of -$8.7 million.
• Across the five-year window, Free Cash Flow plunged 6166.19% in 2022 and soared 69.05% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$7.9 million in 2022, then slipped by 21.32% to -$9.5 million in 2023, then soared by 43.32% to -$5.4 million in 2024, then surged by 69.05% to -$1.7 million in 2025, then sank by 295.28% to -$6.6 million in 2026.
• Per Business Quant, the three latest TLSI Free Cash Flow figures stand at -$6.6 million (Q1 2026), -$1.7 million (Q4 2025), and -$4.6 million (Q3 2025).